Results 161 to 170 of about 297,779 (263)

Biomarkers of ocular surface disease using impression cytology [PDF]

, 2017
Aronni S, Baudouin C, Brignole F, Danjo Y, Eberwein P, Hagan S, Kurpińska M, Mocanu CL, Roy P, Shiraki Y, Suzanne Hagan   +10 more
core   +2 more sources

Hyperthyroid heart disease: Diagnostic and therapeutic aspects [PDF]

, 1990
Reinwein, Dankwart, Scriba, P. C., Scriba, Peter Christian   +2 more
core   +1 more source

Update on thyroid-associated Ophthalmopathy with a special emphasis on the ocular surface [PDF]

, 2016

core   +1 more source

Sirolimus for the treatment of Graves' orbitopathy. [PDF]

Thyroid Res
Comi S, Sabini E, Cosentino G, Santini F, Marinò M.   +4 more
europepmc   +1 more source

Assessment of disease activity in Graves' orbitopathy. [PDF]

Front Ophthalmol (Lausanne)
Potvin ARGG, Lacraru IC, Bisschop PH, de Win MML, Eckstein AK, Saeed P.   +5 more
europepmc   +1 more source

Selenium Supplementation in Graves' Orbitopathy: Effects on Blood Concentrations and Clinical Outcomes. [PDF]

Clin Ophthalmol
Lumyongsatien M, Vejsitthangkul K, Treebuppachatsakul T, Sintuwong S, Nimitwongsakul O, Pongpirul K.   +5 more
europepmc   +1 more source

Unravelling the pathogenic mechanisms in Graves' orbitopathy. [PDF]

Eur Thyroid J
Lee ACH, Kahaly GJ.
europepmc   +1 more source

Sarilumab in the management of Graves orbitopathy with low clinical activity scores. [PDF]

Sci Rep
Pérez-Moreiras J, Abelenda D, Providência J, Castela G.   +3 more
europepmc   +1 more source

Correction: Role of the suppressor of cytokine signaling-3 in the pathogenesis of Graves' orbitopathy. [PDF]

Front Endocrinol (Lausanne)
Kim W, Seo MK, Kim YJ, Choi SH, Ku CR, Kim S, Lee EJ, Yoon JS.   +7 more
europepmc   +1 more source

Real world effectiveness of Mycophenolate-sodium therapy in patients at risk with Graves' orbitopathy. [PDF]

Thyroid Res
Sander J, Al-Ghazzawi K, Bechrakis N, Chen Y, Neumann I, Eckstein A, Oeverhaus M.   +6 more
europepmc   +1 more source